Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial

 

Show simple item record

dc.contributor.author Decloedt, Eric H
dc.contributor.author Lesosky, Maia
dc.contributor.author Maartens, Gary
dc.contributor.author Joska, John A
dc.date.accessioned 2017-03-30T09:31:59Z
dc.date.available 2017-03-30T09:31:59Z
dc.date.issued 2017-02-04
dc.identifier.citation Decloedt, E. H., Lesosky, M., Maartens, G., & Joska, J. A. (2017). Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. AIDS Research and Therapy, 14(1), 6.
dc.identifier.uri http://dx.doi.org/10.1186/s12981-017-0134-2
dc.identifier.uri http://hdl.handle.net/11427/24111
dc.description.abstract Background: The prevalence of bipolar disorder in HIV-infected patients is higher than the general population. Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could be additive, or a pharmacokinetic interaction may occur at renal transporters with a decrease in TDF elimination. Objective: We report on the change in estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease formula in participants who received ART including TDF and were enrolled in a 24 week randomised trial of lithium versus placebo in patients with HIV-associated neurocognitive impairment. Methods: We included HIV-infected adults with cognitive impairment established on ART for at least 6 months with a suppressed viral load attending public sector ART clinics in Cape Town, South Africa. We excluded participants with an eGFR or increase in potassium between the two arms during the 24 weeks. Conclusions: We found that 24-week treatment of HIV-infected patients with lithium and TDF did not result in increased nephrotoxicity.
dc.language.iso en
dc.publisher BioMed Central
dc.rights This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject.other South Africa
dc.subject.other Randomised placebo-controlled clinical trial
dc.subject.other HIV-associated neurocognitive impairment
dc.subject.other HIV
dc.subject.other Lithium
dc.subject.other Placebo
dc.subject.other Antiretroviral therapy
dc.subject.other Tenofovir
dc.title Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial
dc.type Journal Article en_ZA
dc.date.updated 2017-02-04T19:06:10Z
dc.rights.holder The Author(s)
uct.type.publication Research en_ZA
uct.type.resource Article en_ZA
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Health Sciences en_ZA
dc.publisher.department Division of Clinical Pharmacology en_ZA
uct.type.filetype Text
uct.type.filetype Image
dc.identifier.apacitation Decloedt, E. H., Lesosky, M., Maartens, G., & Joska, J. A. (2017). Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. http://hdl.handle.net/11427/24111 en_ZA
dc.identifier.chicagocitation Decloedt, Eric H, Maia Lesosky, Gary Maartens, and John A Joska "Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial." (2017) http://hdl.handle.net/11427/24111 en_ZA
dc.identifier.vancouvercitation Decloedt EH, Lesosky M, Maartens G, Joska JA. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. 2017; http://hdl.handle.net/11427/24111. en_ZA
dc.identifier.ris TY - Journal Article AU - Decloedt, Eric H AU - Lesosky, Maia AU - Maartens, Gary AU - Joska, John A AB - Background: The prevalence of bipolar disorder in HIV-infected patients is higher than the general population. Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could be additive, or a pharmacokinetic interaction may occur at renal transporters with a decrease in TDF elimination. Objective: We report on the change in estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease formula in participants who received ART including TDF and were enrolled in a 24 week randomised trial of lithium versus placebo in patients with HIV-associated neurocognitive impairment. Methods: We included HIV-infected adults with cognitive impairment established on ART for at least 6 months with a suppressed viral load attending public sector ART clinics in Cape Town, South Africa. We excluded participants with an eGFR or increase in potassium between the two arms during the 24 weeks. Conclusions: We found that 24-week treatment of HIV-infected patients with lithium and TDF did not result in increased nephrotoxicity. DA - 2017-02-04 DB - OpenUCT DO - 10.1186/s12981-017-0134-2 DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2017 T1 - Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial TI - Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial UR - http://hdl.handle.net/11427/24111 ER - en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License Except where otherwise noted, this item's license is described as This article is distributed under the terms of the Creative Commons Attribution 4.0 International License